Farrerol and the miR-29b-3p/sirtuin 1 pathway: A mechanistic breakthrough in protecting the diabetic heart

Diabetic cardiomyopathy (DCM) is a cardiac muscle disorder that causes heart failure independently of coronary artery disease. This condition remains a major clinical challenge, as current therapies primarily address traditional risk factors rather than the underlying molecular pathology. In this regard, endothelial dysfunction in the cardiac microvasculature is a key factor in DCM, linking metabolic alterations to impaired myocardial perfusion and fibrosis. Ferroptosis is a unique form of iron-dependent, regulated cell death characterized by lipid peroxidation. This mechanism has been linked to various diabetic complications, although its role in chronic diabetic heart disease remains unclear. In this editorial, we discuss new evidence highlighting endothelial cell ferroptosis as a key mechanism in DCM and a promising therapeutic target. Specifically, we discuss the recent study by Guo <i>et al</i>, demonstrating that farrerol, a natural flavonoid, improves DCM in mice by inhibiting endothelial ferroptosis through the microRNA-29b-3p/sirtuin 1 signaling axis. The findings of Guo <i>et al</i> reveal that downregulation of microRNA-29b-3p by farrerol is able to restore sirtuin 1 levels in cardiac endothelial cells, activating antioxidant defenses and preventing ferroptotic injury. Importantly, the endothelial protection generated by Farrerol translated into improvements in cardiac function and a reduction in fibrosis in diabetic mice. These results open a new therapeutic opportunity for the treatment of DCM by targeting the cardiac microvascular endothelium. Future studies should build on this mechanistic knowledge, addressing the challenges of converting Farrerol, a natural compound with antioxidant and antiferroptotic properties, or other ferroptosis inhibitors into targeted therapies that safely benefit patients with diabetic heart disease.